Physician profile
George C In
NPI 1902835077
$14,354.61
in general payments reported to CMS, 2019-2025
23 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,606 · 2020: $2,293 · 2021: $1,236 · 2022: $574 · 2023: $282 · 2024: $236 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $6,157.05 | 2019-2023 | |
| Abbvie INC. | $5,269.63 | 2019-2022 | |
| Amgen INC. | $921.25 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $287.40 | 2019-2020 | |
| Digestive Care, INC. | $283.82 | 2023-2025 | Pertzye |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $173.91 | 2022-2025 | Strensiq |
| Nestle Healthcare Nutrition INC. | $135.79 | 2020-2022 | |
| Shire North American Group INC | $135.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Novo Nordisk INC | $106.92 | 2021 | |
| Alnylam Pharmaceuticals INC. | $66.37 | 2022-2024 | Givlaari |
| Kyowa Kirin, INC. | $54.75 | 2023 | Crysvita |
| Integra Lifesciences Corporation | $50.84 | 2023 | Integra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $46.80 | 2023 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $34.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.27 | 2021 | |
| Astellas Pharma US INC | $21.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.78 | 2019 | |
| Merck Sharp & Dohme LLC | $14.08 | 2019 | |
| Allergan, INC. | $12.48 | 2019 | |
| Eisai INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George In listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.